Dementia is a challenging constellation of pathology, symptoms, and treatment modalities.
Multiple etiologies for dementia have been proposed, resulting in numerous research attempts
at determining the underlying causes and potential therapeutic approaches. Currently, psycho
pharmacological management of dementia, particularly Alzheimer's disease, focuses on the
manifested cognitive and noncognitive symptoms. This article provides an overview and descrip
tion of dementia, explores current and investigational agents used in the treatment of accompa
nying cognitive and noncognitive symptoms, and suggests considerations for assessing certain
aspects of pharmacological management.
Get full access to this article
View all access options for this article.
References
1.
Aisen, P.S., Marin, D., Altstiel, L., Goodwin, C., Baruch, B., Jacobson, R., Ryan, T., & Davis, K.L. (1996). A pilot study of prednisone in Alzheimer's disease . Dementia, 7, 201-206.
2.
Alexopoulos, G.S. (1996). The treatment of depressed demented patients. Journal of Clinical Psychiatry, 57(Suppl.14), 14-20.
3.
Allain, H., Bentue-Ferrer, D., Gandon, J.M., LeDoze, F., & Belliard, S. (1997). Drugs used in Alzheimer's disease and neuroplasticity . Clinical Therapeutics, 19, 4-15.
4.
Alzheimer's Association, Inc. (1995). Alzheimer's Association 1995 national public policy program to conquer Alzheimer's disease. [On-line]. Available: http:www.alz.org/assoc/media/7.html
5.
American Association of Retired Persons. ( 1993). Coping and caring: Living with Alzheimer's disease [Brochure] . Washington, DC: Author.
6.
American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (4th ed.). Washington, DC: Author .
7.
Antuono, P.G. (1995). Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. Archives of Internal Medicine , 155, 1766-1772.
8.
Auer, S.R., Monteiro, I.M., & Reisberg, B. (1996). The Empirical Behavioral Pathology in Alzheimer's Disease (E-BEHAVE-AD) rating scale. International Psychogeriatrics , 8, 247-266.
9.
Becker, R., & Giacobini, E. (Eds.). (1996). Alzheimer disease: From molecular biology to therapy. Boston: Birkhauser.
10.
Bentley, K.J. (1998). Psychopharmacological treatment of schizophrenia: What social workers need to know. Research on Social Work Practice, 8, 384-405.
11.
Birge, S.J. (1997). The role of estrogen in the treatment of Alzheimer's disease. Neurology, 48(5, Suppl.7), S36-S41.
Cohen-Mansfield, J. (1996). Assessment of agitation. International Psychogeriatrics, 8, 233-245.
14.
Cohen-Mansfield, J., Reisberg, B., Bonnema, J., & Berg, L. (1996). Staging methods for the assessment of dementia: Perspectives. Journal of Clinical Psychiatry, 57, 190-198.
15.
Colenda, C.C., Rapp, S.R., Leist, J.C., & Poses, R.M. (1996). Clinical variables influencing treatment decisions for agitated dementia patients: Survey of physician judgments. Journal of the American Geriatrics Society, 44, 1375-1379.
16.
Cnsmon, M.L. (1994). Tacrine: First drug approved for Alzheimer's disease . Annals of Pharmacotherapy, 28, 744-751.
17.
Cummings, J.L. (1997). The Neuropsychiatric Inventory: Assessing psychopathology in dementia patients. Neurology, 48(5, Suppl.6), S10-S16.
18.
Davis, K.L., Thal, L.J., Gamzu, E.R., Davis, C.S., Woolson, R.F., Gracon, S.I., Drachman, D.A., Schneider, L.S., & Whitehouse, P.J. (1992). A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. New England Journal of Medicine, 327, 1253-1259.
19.
Doraiswamy, P.M., Bieber, F., Kaiser, L., Connors, K., Krishnan, K.R., Reuning-Scherer, J., & Gulanski, B. (1997). Memory, language, and praxis in Alzheimer's disease: Norms for outpatient climcal trial populations. Psychopharmacology Bulletin, 33, 123-128.
20.
Drug Facts and Comparisons (DF&C. (1997). St. Louis, MO: Facts and Comparisons.
21.
Dziegielewski, S.F. (1998). Psychopharmacology and social work practice: Introduction . Research on Social Work Practice, 8, 371-383.
22.
Dziegielewski, S.F., & Leon, A.M. (1998). Psychopharmacological treatment of major depression . Research on Social Work Practice, 8, 475-490.
23.
Evans, D.A. (1990). Estimated prevalence of Alzheimer's disease in the U.S. Millbank Quarterly, 68, 267-289.
24.
Filley, C.M. (1997). Alzheimer's disease in women. American Journal of Obstetncs and Gynecology, 176(1, Pt. 1), 1-7.
25.
Finkel, S.I., & Cooler, C. (1996). Clinical experiences and methodologic challenges in conducting clinical trials on the behavioral disturbances of dementia. International Psychogeriatrics, 8(Suppl.2), 151-163.
26.
Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12, 189-198.
27.
Gidal, B.E., Crismon, M.L., Wagner, M.L., Fagan, S.C., Privitera, M.D. , Dalmady-Israel, C. , & Graves, N.M. (1996). Current developments in neurology, part 2: Advances in the pharmacotherapy of Alzheimer disease, Parkinson's disease, and stroke. Annals of Pharmacotherapy , 30, 1446-1451.
28.
Gooch, M.D., & Stennett, D.J. (1996). Molecular basis of Alzheimer's disease. American Journal of Health-System Pharmacists, 53, 1545-1557.
29.
Gutzmann, H., Kuhl, K.P., Kanowski, S., & Khan-Boluki, J. (1997). Measuring the efficacy of psychopharmacological treatment of psychomotonc restlessness in dementia Clinical evaluation of tiapride. Pharmacopsychiatry, 30, 6-11.
30.
Henderson, V.W. , Watt, L., & Buckwalter, J.G. (1996). Cognitive skills associated with estrogen replacement in women with Alzheimer's disease. Psychoneuroendocrinology, 21, 421-430.
31.
Knapp, M.J., Knopman, D.S., Solomon, P.R., Pendlebury, W.W., Davis, C.S. , & Gracon, S.I. (1994). A 30-week randomized controlled trial of high-dose tacnne in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 985-991.
32.
Lantz, M.S., & Mann, D. (1996). Pharmacologic treatment of agitation in dementia: A comprehensive review. Journal of Geriatric Psychiatry & Neurology, 9(3), 107-119.
33.
Loeb, C., & Meyer, J.S. (1996). Vascular dementia: Still a debatable entity? Journal of Neurological Sciences, 143, 31-40.
34.
McShane, R., Keene, J., Gedling, K., Fairburn, C., Jacoby, R., & Hope, T. (1997). Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropy follow up. British Medical Journal, 314(7076), 266-270.
35.
Mohr, E., Walker, D., Randolph C., Sampson, M., & Mendis, T. (1996). Utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. International Psychogeriatrics , 8, 397-411.
36.
Mohs, R.C. (1996). The Alzheimer's Disease Assessment Scale. International Psychogeriatncs, 8, 195-203.
37.
Molnar, F.J., & Dalziel, W.B. (1997). The pharmacoeconomics of dementia therapies. Bringing the clinical, research, and economic perspectives togetherDrugs & Aging, 10, 219-233.
38.
Morgan, C.D., & Baade, L.E. (1997). Neuropsychological testing and assessment scales for dementia of the Alzheimer's typePsychiatric Clinics of North America, 20(1), 25-43.
39.
Nordberg, A. (1996). Pharmacological treatment of cognitive dysfunction in dementia disordersActa Neurologica Scandanavia Supplementum , 168, 87-92.
40.
Ohkura, T., Isse, L., Akazawa, K., Hamamoto, M., Yaoi, Y., & Hagino, N. (1995). Long-term estrogen replacement therapy in female patients with dementia of the Alzheimer's type. Dementia, 6, 99-107.
41.
Parnetti, L. (1995) Clinical pharmacokinetics of drugs for Alzheimer's disease. Clinical Pharmacokinetics, 29, 110-129.
42.
Parnetti, L., Senin, U., & Mecocci, P. (1997). Cognitive enhancement therapy for Alzheimer's disease: The way forward. Drugs, 53, 752-768.
43.
Pettegrew, J.W., Klunk, W.E., Panchalingam, K., Kanfer, J.N., & McClure, R.J. (1995) Clinical and neurochemical effects of acetyl-1-carnitine in Alzheimer's disease. Neurobiology & Aging, 16, 1-4.
44.
Rabins, P.V. (1996) Developing treatment guidelines for Alzheimer's disease and other dementias. Journal of Clinical Psychiatry , 57(Suppl.14), 37-38.
45.
Reisberg, B., Auer, S.R., Monteiro, I., Boksay, I., & Sclan, S.G. (1996). Behavioral disturbances of dementia: An overview of phenomenology and methodologic concerns. International Psychogeriatrics, 8(Suppl.2), 169-182.
46.
Reisberg, B., Ferns, S.H., de Leon, J.H., & Crook, T. (1982). The global deterioration scale for assessment of pnmary degenerative dementia. American Journal of Psychiatry , 139, 1136-1139.
Rogers, S.L., & Friedhoff, L.T. (1996). The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a U.S. multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group . Dementia, 7(6), 293-303.
49.
Saletu, B., Paulus, E., Linzmayer, L., Anderer, P., Semlitsch, H.V., Grunberger, J., Wicke, L., & Neuhold, A. (1995). Nicergoline in senile dementia of Alzheimer type and multi-infarct dementia: A double-blind, placebo-controlled, clinical and EEG-ERP mapping study. Psychopharmacology, 177, 385-395.
50.
Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., Schneider, L.S., Thal, L.J. (1997). A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. New England Journal of Medicine, 336, 1216-1222.
51.
Schneider, L.S. (1996). New therapeutic approaches to Alzheimer's disease . Journal of Clinical Psychiatry, 57(Suppl.14), 30-36.
52.
Schneider, L.S. , Farlow, M.R., Henderson, V.W., Pogoda, J.M. (1996). Effects of estrogen replacement therapy on response to tacnne in patients with Alzheimer's disease. Neurology , 46, 1580-1584.
53.
Shvaloff, A., Neuman, E., & Guez, D. (1996). Lines of therapeutics research in Alzheimer's disease. Psychopharmacology Bulletin, 32, 343-352.
54.
Shrotriya, R.C., Cutler, N.R., Sramek, J.J., Veroff, A.E., & Hironaka, D.Y. (1996). Efficacy and safety of BMY 21,502 in Alzheimer disease. Annals of Pharmacotherapy , 30, 1376-1380.
55.
Sundel, M., & Sundel, S.S. (1998). Psychopharmacological treatment of panic disorder . Research on Social Work Practice, 8, 426-451.
56.
Thal, L.J., Fuld, P.A., & Masur, D.M. (1983). Oral physostigmine and lecithin improve memory m Alzhiemer's disease. Annals of Neurology, 13, 491-496.
57.
Thal, L.J., Masur, D.M., & Blau, A.D. (1989). Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease. Journal of the American Geriatrics Society, 37, 42-48.
58.
Wallin, A., Edman, A. , Blennow, K., Gottfries, C.G., Karlsson, I., Regland, B., & Sjogren, M. (1996). Stepwise comparative status analysis (STEP): A tool for identification of regional brain syndromes in dementia. Journal of Geriatric Psychiatry and Neurology, 9(4), 185-199.
59.
Walsh, J. (1998). Psychopharmacological treatment of bipolar disorder . Research on Social Work Practice, 8, 406-425.
60.
Walstra, G.J., Teunisse, S., vanGool, W.A., & vanCrevel, H. (1997). Reversible dementia in elderly patients referred to a memory clinic. Journal of Neurology, 244, 17-22.
61.
Watkins, P.B., Zimmerman, H.J., Knapp, M.J., Gracon, S.I., & Lewis, K.W. (1994). Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease. Journal of the American Medical Association, 271, 992-998.
62.
Whitehouse, P.J., Sciulli, C.G., & Mason, R.M. (1997). Dementia drug development: Use of information systems to harmonize global drug development. Psychopharmacology Bulletin, 33, 129-133.
63.
Wilson, A.L., Langley, L.K., Monley, J., Bauer, T., Rottunda, S., McFalls, E., Kovera, C., & McCarten, J.R. (1995). Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. Pharmacology, Biochemistry, and Behavior, 51, 509-514.
64.
Wind, A.W., Schellevis, F.G., Van Straveren, G., Scholten, R.P., Jonker, C., & Van Eijk, J.T. (1997). Limitations of the Mini-Mental State Examination in diagnosing dementia in general practice. International Journal of Geriatric Psychiatry, 12, 101-108.
65.
Zaudig, M. (1996). Assessing behavioral symptoms of dementia of the Alzheimer's type: Categorical and quantitative approaches. International Psychogeriatrics, 8(Suppl.2), 183-200.
